Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma

Autor: Karavasilis, V., Malamou-Mitsi, Vassiliki D., Briassoulis, E. Ch, Tsanou, E., Kitsou, E., Pavlidis, Nicholas
Přispěvatelé: Pavlidis, Nicholas [0000-0002-2195-9961], Karavasilis, V. [0000-0002-5806-9399]
Rok vydání: 2006
Předmět:
Vascular Endothelial Growth Factor A
Pathology
Angiogenesis
CD34
Antigens
CD34

Platinum Compounds
Ovarian neoplasms
Gynecologic surgery
Thrombospondin 1
Neovascularization
chemistry.chemical_compound
Gynecologic Surgical Procedures
Cancer surgery
Microvasculature
Gynecologic surgical procedures
Vascular endothelial growth factor a
Ovarian carcinoma
Antineoplastic agents
Neovascularization
Pathologic/*physiopathology

Cd34
Middle aged
Quantitative analysis
Priority journal
Platinum compounds
Ovarian Neoplasms
Platinum derivative
Neovascularization
Pathologic

Correlation analysis
Obstetrics and Gynecology
Cancer diagnosis
Middle Aged
Cancer classification
Immunohistochemistry
Vascular endothelial growth factor
Vascular endothelial growth factor A
Tissue distribution
Antineoplastic agent
Oncology
Adenocarcinoma
Female
Cancer chemotherapy
medicine.symptom
Protein determination
Human
Thrombospondin-1
Adult
endocrine system
medicine.medical_specialty
Microvessel density
Vascular Endothelial Growth Factor A/analysis/*biosynthesis
Histopathology
Antineoplastic Agents
Major clinical study
Article
Cancer grading
Tumor vascularization
Platinum Compounds/therapeutic use
medicine
Humans
Antigens
CD34/analysis/*biosynthesis

Tumor marker
Human tissue
Antigens
Neoplasm Staging
Aged
Tumor biopsy
Cd34 antigen
Pathologic
Vasculotropin
Ovary carcinoma
business.industry
Microcirculation
Adenocarcinoma/chemistry/*metabolism/*pathology/therapy
Ovarian Neoplasms/chemistry/*metabolism/*pathology/therapy
Antineoplastic Agents/therapeutic use
medicine.disease
Cancer survival
Thrombospondin 1/analysis/*biosynthesis
chemistry
Neoplasm staging
Cancer patient
Protein expression
Disease marker
Ovarian cancer
business
Controlled study
Zdroj: International Journal of Gynecological Cancer
ISSN: 1525-1438
1048-891X
DOI: 10.1136/ijgc-00009577-200602001-00039
Popis: The aim of the study was to investigate angiogenesis in patients with advanced-stage ovarian carcinoma. We used paraffin-embedded tumor tissues from 33 patients diagnosed with FIGO III ovarian cancer who had optimal surgery and received platinum-based chemotherapy. The tissue expression of CD34, vascular endothelial growth factor (VEGF), and thrombospondin-1 (TSP-1) was assessed immunohistochemically. CD34 stained hot spot areas were used to evaluate tumor microvessel density (MVD). VEGF and TSP-1 were assessed by semiquantitative methods. The studied molecules were investigated for relationship with standard clinicopathologic parameters. MVD count was high: median value of 39, range 12–143 microvessels/mm2. VEGF was present in all cases and stained strong in 91%. Stroma staining for TSP-1 was weak in 79% of the cases, strong in 6%, and absent in five (15%). We did not find correlations between the three studied markers and histologic type or tumor grade. MVD score did not relate to VEGF or TSP-1. We only observed a trend toward a longer survival in patients with tumors expressing high TSP-1 (60 vs. 36 months, P= 0.1). Proangiogenetic factor VEGF is highly expressed in advanced-stage ovarian carcinomas. The findings of this study may offer support for considering VEGF-targeted therapeutics in ovarian cancer treatment research.
Databáze: OpenAIRE